Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2006; 12(35): 5692-5698
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Published online Sep 21, 2006. doi: 10.3748/wjg.v12.i35.5692
Table 1 Demographic data of the hepatitis C patients
| Variable | Group A(PEG-IFN+RBV)n = 38 | Group B(IFN+RBV)n = 35 | P |
| Age (yr) (mean ± SD) | 45.5 ± 6.1 | 45.4 ± 5.8 | NS1 |
| Gender | |||
| Male | 31 (81.6) | 33 (94.3) | |
| Female | 7 (18.4) | 2 (5.7) | |
| Body mass (mean ± SD) | |||
| Before treatment | 81.9 ± 12.0 | 73.6 ± 7.7 | 0.001 |
| After Treatment | 78.9 ± 12.5 | 71.1 ± 7.4 | 0.002 |
| Weight reduction | 2.9 ± 4.3 | 2.6 ± 2.7 | NS1 |
| Inflammation stage | |||
| 0-1 | 7 (18.4) | 8 (22.9) | NS1 |
| 2-3 | 31 (81.6) | 27 (77.1) | |
| Grade of fibrosis | |||
| Mild (0-2) | 25 (65.8) | 23 (65.7) | NS1 |
| Severe (3-4) | 13 (34.2) | 12 (34.3) | |
| Bilharzial co-infection No. | 31 (81.6) | 30 (5.7) | |
- Citation: Derbala M, Kaabi SA, Dweik NE, Pasic F, Butt M, Yakoob R, Al-Marri A, Amer A, Morad N, Bener A. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006; 12(35): 5692-5698
- URL: https://www.wjgnet.com/1007-9327/full/v12/i35/5692.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i35.5692